What is risk-stratified breast screening and how does it differ from what we have now?

Currently, all women aged 50–74 are invited for a free mammogram every two years, and women aged 40 and over can self-refer at any time. Risk-stratified screening would personalise this: women at higher risk — due to dense breast tissue, family history, or genetic factors such as BRCA variants — might screen more frequently or via additional modalities. Women at genuinely lower risk might screen less often. The goal is to find more cancers in the people most likely to have them, and reduce over-investigation in those who aren't.

I'm in my 40s — does this change apply to me now?

Not yet in its full form. Women aged 40 and over can already access free BreastScreen mammography without a GP referral. The announced change is a strategic direction, not an immediate policy shift — implementation is planned within 10 years, with a pilot beginning in the 45–49 age group. If you're in your 40s and have risk factors such as a strong family history of breast or ovarian cancer, or dense breast tissue noted on a prior mammogram, speak with your GP about your individual screening needs now rather than waiting.

BreastScreen plans personalised mammography within ten years

What just happened

BreastScreen Australia has released a “Strategic Framework for the Future of BreastScreen Australia,” announcing a fundamental shift in how Australia’s national breast cancer screening programme will work. The framework, developed in response to a 2025 national policy and funding review, commits to transitioning from population-wide biennial mammography toward personalised, risk-stratified screening over the next ten years.

The current model is straightforward: all women aged 50 to 74 receive a biennial invitation for a free mammogram via BreastScreen, and women aged 40 and over can self-refer for free screening at any point. The new model changes the underlying logic — instead of treating all women in an age band as equivalent, screening will eventually be tailored to each person’s individual risk profile.

Two immediate steps have been announced. First, BreastScreen will begin notifying women about their breast density — information that currently generates a report that does not routinely reach patients in plain, usable form. Second, a pilot programme for women aged 45 to 49 will trial different screening approaches specifically for this age group. That age group has historically been one of the most contested in breast screening policy internationally.

Both-and

Why personalised screening makes sense

The case for risk stratification is substantive. Breast density is one of the most significant independent risk factors for breast cancer. Dense breast tissue both increases cancer risk and reduces mammogram sensitivity — dense tissue appears white on a mammogram, and so does cancer, making it harder to detect. Women with very dense breast tissue are getting less benefit from standard mammography than the population average suggests, and most of them don’t know their density status.

Genetic risk adds a second layer. Women with a pathogenic variant in BRCA1, BRCA2, PALB2, or other high-penetrance genes face lifetime breast cancer risks that are substantially higher than population averages. Current clinical guidelines recommend much more intensive surveillance for this group — including MRI alongside mammography. But connecting these women to appropriate surveillance depends on them knowing their risk and having a GP conversation about it.

Family history sits in between: not as high-risk as a known pathogenic variant, but still meaningfully elevated above the population baseline. Many women in this group are currently receiving the same biennial mammogram invitation as women with no family history at all.

Risk-stratified screening addresses all three layers: identify the higher-risk women, screen them more intensively and with more sensitive modalities where appropriate, and potentially lengthen intervals for genuinely lower-risk women where the evidence suggests standard two-yearly mammography may not be necessary.

The complexity of actually doing this

The contested part of risk stratification is implementation. It requires risk-assessment tools that are feasible to use at scale, accessible genetic testing for appropriate individuals, breast density information communicated clearly to patients and GPs, and integration with general practice — which holds most of the relevant family history and comorbidity information that risk algorithms need.

The ten-year timeline in the framework is an honest acknowledgement of this complexity. This is not a simple operational change; it requires infrastructure, training, and evidence generated from the pilots before it can scale nationally.

The pilot programme for women aged 45 to 49 matters for another reason. This is exactly the age group where breast cancer incidence begins rising appreciably — incidence rates increase significantly through the late 40s and 50s — where many women are focused on perimenopause and not necessarily thinking about breast screening, and where the existing biennial-from-50 model may leave some higher-risk individuals under-surveilled in precisely the window where it matters. The pilot targeting this age group is a sensible place to generate real-world evidence.

What stays the same for now

The existing programme continues. Women aged 50 to 74 continue to receive biennial invitations. Women aged 40 and over can continue to self-refer without a GP referral. The framework is a strategic direction — it shapes where the programme is heading over the next decade, not what happens at the appointment you have next month.

My two cents

If you’re in your 40s or early 50s and haven’t been screened recently, the immediate practical message doesn’t require waiting for the new model: self-referral to BreastScreen is free, doesn’t require a GP referral, and is available now.

The longer-term message is that breast screening is finally moving toward the kind of personalised risk conversation that makes clinical sense. Knowing your breast density — which this framework prioritises communicating — is genuinely useful information. “Dense breast tissue” has been recorded in BreastScreen reports for years without patients receiving a clear explanation of what it means for their risk or their next steps.

If you have a significant family history of breast or ovarian cancer, or you’ve been told at any point that you have dense breast tissue, this is a reason to have a specific conversation with your GP about your individual screening approach now, rather than waiting for the national programme to catch up over the next decade.

The 45 to 49 cohort being explicitly targeted in the pilot is also worth noting. This is an age group that has consistently slipped through the default invitation threshold at 50, and where a substantial number of breast cancers present in women whose risk would have justified earlier or more intensive screening.

Verdict: maybe — nothing changes immediately, but if you’re in your 40s or have elevated risk factors, speak with your GP about your current screening schedule.

Sources cited

BreastScreen Australia plans move to risk-stratified screening within 10 years. AusDoc, 18 August 2026. https://www.ausdoc.com.au/news/breastscreen-australia-plans-move-to-risk-stratified-screening-within-10-years/
BreastScreen Australia. Australian Government Department of Health and Aged Care. https://www.breastscreen.info.au